L-Cysteine HCl Injection Rx
Generic Name and Formulations:
L-Cysteine HCl 50mg/mL; soln for IV infusion after dilution; contains aluminum, sulfur; preservative-free.
Indications for L-Cysteine HCl Injection:
An additive to crystalline amino acid injections to meet essential nutritional requirements for infants given TPNs.
See literature. Rotate inj site. Give by central venous infusion. Add 0.5g L-Cysteine with 12.5g crystalline amino acid injection; dilute as indicated.
Hepatic coma. Metabolic disorders (eg, impaired nitrogen utilization).
Hepatic, renal, pulmonary, or cardiac insufficiency. Hyperkalemia. Metabolic or respiratory alkalosis. Monitor hepatic and renal function; discontinue if BUN levels exceed normal postprandial limits and continue to rise. Monitor blood (eg, CBC, ammonia, glucose, electrolytes, cholesterol, acid-base balance, serum proteins, osmolarity), urine osmolarity and glucose during therapy. Premature neonates. Pregnancy.
Concomitant tetracycline reduces nitrogen sparing effects.
Local reactions (eg, warm sensation, erythema, phlebitis, thrombosis), flushing, fever, nausea.
Single-dose vials (10mL)—10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- IL-23 Drives Castration-Resistant Prostate Cancer
- Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer
- Lenalidomide-Based Maintenance Therapy May Be the Most Effective in Myeloma
- Approximately Two-Thirds of Patients With Stage IV Bladder Cancer Remain Untreated
- Aspirin and Colorectal Cancer